University of Liverpool researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the treatment of life threatening invasive fungal infections such as invasive aspergillosis.
Invasive fungal infections are common and often lethal. Despite optimal medical care mortality is 20-30% at six weeks and dramatically rises to 80-100% for drug resistant infection.
These infections occur most commonly in the context of leukemia and bone marrow transplantation and often in young patients with otherwise curable disease.
Orotomides
The researchers, led by Professor William Hope from the University’s Antimicrobial Pharmacodynamics and Therapeutics (APT) Group, have characterised the biochemical and physiologic effects (pharmacodynamics) of F901318, which is the lead compound of the new class of drugs termed the ‘orotomides’.
The ‘orotomides’, discovered by F2G Limited, have a novel mechanism of action which is the specific biochemical interaction through which a drug substance produces its pharmacological effect.
This is the first new class of antifungal agent to be discovered in the last three decades.
The study, which was supported by a research grant by F2G, has been published in mBio.
Clinical studies
APT’s work provides the underpinning evidence for efficacy and dosage justification for the very first patients receiving the new drug. Such information is required by regulatory agencies such as the European Medicines Agency and the Food and Drug Administration before clinical studies can proceed.
Professor Hope, said: “Antifungal resistance represents a major global clinical challenge. This study provides the necessary information to enable F901318 to be developed for clinical use.”
Learn more: Researchers help develop new antifungal drug
The Latest on: Antifungal drug
[google_news title=”” keyword=”antifungal drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Keto Diet Boosts Lifesaving Antifungal Drug in Miceon May 8, 2024 at 2:25 pm
It’s possible that a keto diet influences the gut microbiome in a way that changes how the drug is absorbed. The dietary shift could also boost the immune system, making it easier for the drug to ...
- SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Updateon May 8, 2024 at 1:41 pm
JERSEY CITY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and ...
- WSU Fungus Researcher Awarded Fulbright to U.K.on May 7, 2024 at 4:47 am
Washington State University bioengineering senior Katy Ayers has received a Fulbright U.S. Student award to further her fungus studies at the University of Exeter in southwest England.Her Fulbright sc ...
- Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meetingon May 7, 2024 at 1:00 am
Matinas’ lead LNC-based therapy is MAT2203, an oral formulation of the broad-spectrum antifungal drug amphotericin B, which although highly potent, can be associated with significant toxicity. Matinas ...
- Researchers review current evidence on Candida auris, an emerging multidrug-resistant yeaston May 6, 2024 at 9:56 am
The antifungal resistance of C. auris is a significant public health concern. Mechanistically, this resistance is associated with the alteration of drug targets, activation of cellular stress response ...
- Exeter announces new £3.4 million global funding for solutions to antifungal drug resistanceon May 3, 2024 at 7:50 am
Considering this threat, increasing frequencies of antifungal drug resistance amongst fungi in the natural environment and in patients undergoing hospital treatment means even fewer drugs are ...
- Top 8 Best Antifungal Supplements in 2024on April 29, 2024 at 5:00 pm
Antifungal dietary supplements can aid in combating ... These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure, or ...
- Pulmocide exits OPERA with phase 2 evidence of antifungal safety and efficacyon April 15, 2024 at 2:41 am
Pulmocide has added new nuances to the chorus of evidence for its antifungal, reporting data from the phase 2 OPERA-S study to show the candidate can prevent and eradicate infections without ...
- Changes in Renal Function After Changes in Antifungal Drug Therapyon April 6, 2024 at 5:00 pm
One limitation of our study is that data were collected only during the period of antifungal therapy administration ... (up to 15 days); since the drug is excreted very slowly (over weeks to ...
- Antibacterial and antifungal drug discoveryon February 1, 2022 at 4:33 pm
Table 1 Selected companies and their antibacterial and antifungal programs. Full size table In addition, one of the key issues that characterize the current state of antibiotic drug discovery is ...
via Google News and Bing News